We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,202

When food production leads to prosecution
  • Davis Wright Tremaine LLP
  • European Union, USA
  • March 6 2013

Over the last few weeks, two big stories have made headlines in the food industry. Beginning in early February, news media across Europe began

Wireless industry, scientists debate results of cell phone safety study
  • Paul, Weiss, Rifkind, Wharton & Garrison LLP
  • European Union, USA
  • May 21 2010

The results of a five-year, multimillion dollar study conducted by Interphone on the health effects of cell phone use were lauded by US and European wireless industry officials who say the research validates their position against any conclusive link between mobile phone use and brain tumors

What you need to know about the law relating to the marketing of dietary supplements in the U.S., the EU and China
  • Kelley Drye & Warren LLP
  • China, European Union, USA
  • July 22 2011

Consumers around the world are increasing their use of dietary supplements

New route for cooperation between the E.U. and the U.S. on biosimilars
  • Dechert LLP
  • European Union, USA
  • June 28 2011

The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have set up a new “cluster” on biosimilar medicines

UK Supreme Court steps into line with Europe, but rejects U.S. approach
  • McDermott Will & Emery
  • European Union, United Kingdom, USA
  • November 30 2011

The UK’s highest court recently considered the provisions of the European Patent Convention (EPC) centering on the “susceptible of industrial application” requirement in the context of a patent describing a DNA sequence for a new protein, Neutrokine-α, which was a member of a group of similar proteins known as the TNF ligand superfamily

A comparison of US and EU biosimilars regimes
  • Fenwick & West LLP
  • European Union, USA
  • January 20 2012

Economic barriers, along with regulatory complexity and uncertainty, are shaping the biosimilars industry into something entirely different from the generic small molecule pharmaceutical industry

Antitrust, competition and economic regulation client quarterly newsletter
  • Hogan Lovells
  • China, European Union, Greece, USA
  • January 24 2012

A public company CEO recently consented to a federal district court order requiring him to pay a $500,000 civil penalty for violating the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”

Biosimilar battlegrounds - what is new in biosimilars and where?
  • Bereskin & Parr LLP
  • Canada, European Union, USA
  • February 17 2012

Biosimilars are second entry biologic drugs

Methods of medical treatment claims issues in Canada, US and Europe
  • Gowling Lafleur Henderson LLP
  • Canada, European Union, USA
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe

A clinical trial data sharing commitment between the EU and the US
  • Baker & McKenzie
  • European Union, USA
  • August 19 2013

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the US Pharmaceutical Research and Manufacturers of America (PhRMA